Liabilities / Assets
32nd percentile
Higher debt load relative to assets than 32% of similar nonprofits.
EIN 20-6745475 • 501(c)3 • Needham, MA
Profile
The adenoid cystic carcinoma research foundation (accrf) supports research into adenoid cystic carcinoma that will accelerate the development of improved therapies and a cure for the disease.
Precomputed percentiles relative to similar nonprofits. These scores are descriptive rather than judgmental.
Liabilities / Assets
32nd percentile
Higher debt load relative to assets than 32% of similar nonprofits.
Liabilities / Revenue
34th percentile
Higher debt load relative to revenue than 34% of similar nonprofits.
Net Margin
11th percentile
Higher net margin than 11% of similar nonprofits.
Top Officer Pay
82nd percentile
Higher top officer pay than 82% of similar nonprofits.
Top officer pay equals 13.1% of source-year revenue.
Asset Growth
12th percentile
Faster asset growth than 12% of similar nonprofits.
Revenue Growth
8th percentile
Faster revenue growth than 8% of similar nonprofits.
Assets
Down$2,251,893
Down $438,877 (-16%) from 2023
Liabilities
Down$20,252
Down $126,874 (-86%) from 2023
Net Assets
Down$2,231,641
Down $312,003 (-12%) from 2023
Revenue
Down$1,146,195
Down $747,350 (-39%) from 2023
Expenses
Down$1,458,198
Down $414,522 (-22%) from 2023
Net Income
Down-$312,003
Down $332,828 (-1598%) from 2023
Most recent year
2024 • Form 990Detailed filing. Detailed filing data is available for this year.
The adenoid cystic carcinoma research foundation (accrf) supports research into adenoid cystic carcinoma that will accelerate the development of improved therapies and a cure for the disease.
Supporting research into the treatment and cure of adenoid cystic carcinoma.
| Line | Beginning | End | Change |
|---|---|---|---|
| Assets | |||
| Savings and Temporary Cash Investments | $2,067,028 | $2,183,175 | ▲ $116,147 |
| Cash and Non-Interest-Bearing Accounts | $79,075 | $47,328 | ▼ $31,747 |
| Accounts Receivable | $523,646 | $21,300 | ▼ $502,346 |
| Prepaid Expenses and Deferred Charges | $21,021 | $90 | ▼ $20,931 |
| Total Assets | $2,690,770 | $2,251,893 | ▼ $438,877 |
| Liabilities | |||
| Grants Payable | $50,000 | $0 | ▼ $50,000 |
| Accounts Payable and Accrued Expenses | $78,026 | $20,252 | ▼ $57,774 |
| Deferred Revenue | $19,100 | $0 | ▼ $19,100 |
| Total Liabilities | $147,126 | $20,252 | ▼ $126,874 |
| Net Assets / Fund Balance | |||
| Net Assets Without Donor Restrictions | $2,543,644 | $2,231,641 | ▼ $312,003 |
| Total Net Assets Fund Balance | $2,543,644 | $2,231,641 | ▼ $312,003 |
| Total Liabilities and Net Assets / Fund Balance | $2,690,770 | $2,251,893 | ▼ $438,877 |
| Name | Title | Full / Part Time | Base | Total |
|---|---|---|---|---|
| Jeffrey a Kaufman | Executive Director/board C | FT | $150,000 | $150,000 |
| Nicole Spardy Burr | Director of Research | FT | $142,500 | $142,500 |
| Name | Title |
|---|---|
| Thomas Dilenge | Board Vice Chair |
| Bozho Todorich | Director |
| David Morse | Director |
| Elizabeth Wehlage | Director |
| Emma Kinloch | Director |
| Marnie a Kaufman | Director & CFO |
| Ralph Mollis | Treasurer |
| Line Item | Amount |
|---|---|
| Other Expenses | $572,816 |
| Grants and Similar Amounts Paid | $464,311 |
| Salaries, Compensation, and Employee Benefits | $421,071 |
| Total Fundraising Expense | $64,763 |
| Professional Fundraising Fees | $0 |
| Line Item | Program | Management | Fundraising | Total |
|---|---|---|---|---|
| Grants to Domestic Orgs | $367,325 | - | - | $367,325 |
| Other Salaries and Wages | $148,764 | $58,568 | $34,222 | $241,554 |
| Current Officers, Directors, Trustees, and Key Employees | $92,379 | $36,369 | $21,252 | $150,000 |
| Foreign Grants | $96,986 | - | - | $96,986 |
| Office Expenses | $36,620 | $5,154 | $3,349 | $45,123 |
| Payroll Taxes | $18,178 | $7,157 | $4,182 | $29,517 |
| Fees for Services Accounting | - | $19,204 | - | $19,204 |
| Conferences and Meetings | $12,193 | - | - | $12,193 |
| Fees for Services Other | - | $2,566 | $1,758 | $4,324 |
| Other Expenses | $1,499 | - | - | $1,499 |
| Insurance | $521 | - | - | $521 |
| Total Functional Expenses | $1,264,417 | $129,018 | $64,763 | $1,458,198 |
| Line Item | Amount |
|---|---|
| Total Expenses per Audited Statements | $1,495,698 |
| Expenses per Audited Statements | $1,458,198 |
| Total Expenses per Form 990 | $1,458,198 |
| Expenses Not Reported on Form 990 | $37,500 |
| Expenses Not Reported on Financial Statements | $0 |
| Recipient | Location | Category | Purpose | Amount |
|---|---|---|---|---|
| Mission Viejo Hospital and Ucla | Mission Viejo, CA | 501(c)(3) | CT-GUIDED LDR BRACHYTHERAPY FOR ADENOID CYSTIC CARCINOMA LUNG METASTASES: EFFICACY AND SAFETY OUTCOMES. | $100,000 |
| Dana Farber Cancer Institute | Boston, MA | 501(c)(3) | STEREOTACTIC BODY RADIOTHERAPY (SBRT) FOR EARLY TREATMENT OF OLIGOMETASTATIC ADENOID CYSTIC CARCINOMA: THE SOLAR TRIAL | $50,000 |
| Mass General | Boston, MA | 501(c)(3) | Chemical Proteomics to Target Myb in Acc | $50,000 |
| Md Anderson Cancer Center | Houston, TX | 501(c)(3) | Vegfr Inhibitors in Adenoid Cystic Carcinoma | $50,000 |
| H Lee Moffitt Cancer Center & Research Institute Inc | Tampa, FL | 501(c)(3) | Molecular Characterization of the Salivary Adenoid Cystic Carcinoma Tumor Immune Landscape by Anatomic Subsite | $49,999 |
| Virgina Commonwealth University of Medicine | Richmond, VA | 501(c)(3) | To Study the Expression of Flower-win and Flower-lose in Adenoid Cystic Carcinoma (acc) | $49,989 |
| Baylor College of Medicine | Houston, TX | 501(c)(3) | Adenoid Cystic Carcinoma Arising at Non-salivary Sites in the U.s.- a Proposal for Analysis of Two National Cancer Datasets. | $36,768 |
| Rutgers Cancer Institute | New Brunswick, NJ | 501(c)(3) | Patterns of Care in the Management of Patients With Adenoid Cystic Carcinoma of the Breast | $30,569 |
| Region | Activity | Services | Offices | Employees | Spending |
|---|---|---|---|---|---|
| Europe (including Iceland & Greenland) | Grants to Recipients Located in Region. | Multicenter Validation of P63 Immunohistochemistry (ihc) as a Prognostic Marker for Adenoid Cystic Carcinoma (instituto Portugus De Oncologia De Lisboa) (radbound University, Netherlands & Instituto Portugues De Oncologia Delisboa, Portugal) and Identifying Novel Treatment Options as Well as Predictive Biomarkers for Existing Immune Therapies in Advanced Acc (charite Comprehensive Cancer Center, Germany) | 0 | 0 | $72,013 |
| East Asia and the Pacific | Grants to Recipients Located in Region. | A Prelude Towards Transforming Adenoid Cystic Carcinoma Into an Immune Hot Tumour (macquarie University, Australia) | 0 | 0 | $24,973 |
| Line Item | Amount |
|---|---|
| Professional Fundraising Fees | $0 |
“The executive director, jeffrey a. Kaufman, is married to a director on the board, marnie a. Kaufman.”
“The form 990 is prepared by the external auditors and reviewed by management. Once all are satisfied with the form, it is finalized and a copy is sent to all directors. The directors are asked if they have any questions or comments and a general review of the form is conducted by management . Revisions and corrections are made as necessary. Subsequently, the form is submitted to the irs.”
“A formal process is undertaken each year to monitor and enforce the conflict of interest policy contained within the bylaws . Each january, an annual survey on conflicts of interest is completed by every director and officer covering the prior calendar year. All business relationships, if any, are reported to the board of directors. Excluding any interested parties, a majority of remaining directors determines whether a conflict of interest has occurred and whether a more advantageous transaction is available to the foundation that would not lead to a conflict of interest. The board is charged with taking appropriate disciplinary and corrective action in the case of a violation of the conflict of interest policy.”
“A formal strategic review, objective setting and performance review process is undertaken each year. The board of directors reviews the performance of the organization and executive director, based on goals and objectives previously agreed upon during the prior calendar year and on a performance report submitted by the executive director in advance. The independent directors of the board meet separately to assess the executive director's performance, agree on a process to inform the executive director of any areas of needed improvement, and agree upon a merit and/or cost of living salary increase for the director , subject to availability of funds and maintenance of an appropriate ratio between such salary and accrf fundraising/revenue totals in any given year . The board of directors sets performance objectives and metrics for the organization and the executive director for the current calendar year.”
“The organization makes its governing documents (articles of incorporation and by-laws}, its conflict of interest policy and financial statements available upon request. The organization will mail copies upon request or provide copies to those who come to the administrative offices during normal business hours.”
“The foundation is exempt from income taxes as a public charity under section 501(c)(3) of the internal revenue code. Management believes that the foundation operates in a manner consistent with their tax-exempt status at both the state and federal level. The foundation annually files irs form 990 - return of organization exempt from income tax, reporting various information that the irs uses to monitor the activities of tax-exempt entities. These tax returns are subject to review by the taxing authorities generally for a period of three years after they were filed. The foundation currently has no tax examinations in progress. The foundation evaluates all significant tax positions. As of december 31, 2024, the foundation does not believe that it has taken any tax positions that would require the recording of any additional tax liability nor does it believe that there are any unrealized tax benefits that would either increase or decrease within the next 12 months. The foundation did not pay any interest or penalties in 2024.”
This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.
| Path | # | Value |
|---|---|---|
| IRS990/AccountantCompileOrReviewInd | 0 | 0 |
| IRS990/AccountsPayableAccrExpnssGrp/BOYAmt | 0 | 78026 |
| IRS990/AccountsPayableAccrExpnssGrp/EOYAmt | 0 | 20252 |
| IRS990/AccountsReceivableGrp/BOYAmt | 0 | 523646 |
| IRS990/AccountsReceivableGrp/EOYAmt | 0 | 21300 |
| IRS990/ActivitiesConductedPrtshpInd | 0 | 0 |
| IRS990/ActivityOrMissionDesc | 0 | SUPPORTING RESEARCH INTO THE TREATMENT AND CURE OF ADENOID CYSTIC CARCINOMA. |
| IRS990/AllOtherContributionsAmt | 0 | 654137 |
| IRS990/AnnualDisclosureCoveredPrsnInd | 0 | 1 |
| IRS990/AuditCommitteeInd | 0 | 1 |
| IRS990/BackupWthldComplianceInd | 0 | 1 |
| IRS990/BooksInCareOfDetail/BusinessName/BusinessNameLine1Txt | 0 | MARNIE A KAUFMAN |
| IRS990/BooksInCareOfDetail/PhoneNum | 0 | 7814491757 |
| IRS990/BooksInCareOfDetail/USAddress/AddressLine1Txt | 0 | 60 SAVOY ROAD |
| IRS990/BooksInCareOfDetail/USAddress/CityNm | 0 | NEEDHAM |
| IRS990/BooksInCareOfDetail/USAddress/StateAbbreviationCd | 0 | MA |
| IRS990/BooksInCareOfDetail/USAddress/ZIPCd | 0 | 02492 |
| IRS990/BusinessRlnWith35CtrlEntInd | 0 | 0 |
| IRS990/BusinessRlnWithFamMemInd | 0 | 0 |
| IRS990/BusinessRlnWithOrgMemInd | 0 | 0 |
| IRS990/CashNonInterestBearingGrp/BOYAmt | 0 | 79075 |
| IRS990/CashNonInterestBearingGrp/EOYAmt | 0 | 47328 |
| IRS990/ChangeToOrgDocumentsInd | 0 | 0 |
| IRS990/CntrctRcvdGreaterThan100KCnt | 0 | 0 |
| IRS990/CollectionsOfArtInd | 0 | 0 |
| IRS990/CompCurrentOfcrDirectorsGrp/FundraisingAmt | 0 | 21252 |
| IRS990/CompCurrentOfcrDirectorsGrp/ManagementAndGeneralAmt | 0 | 36369 |
| IRS990/CompCurrentOfcrDirectorsGrp/ProgramServicesAmt | 0 | 92379 |
| IRS990/CompCurrentOfcrDirectorsGrp/TotalAmt | 0 | 150000 |
| IRS990/CompensationFromOtherSrcsInd | 0 | 0 |
| IRS990/CompensationProcessCEOInd | 0 | 1 |
| IRS990/CompensationProcessOtherInd | 0 | 0 |
| IRS990/ConferencesMeetingsGrp/ProgramServicesAmt | 0 | 12193 |
| IRS990/ConferencesMeetingsGrp/TotalAmt | 0 | 12193 |
| IRS990/ConflictOfInterestPolicyInd | 0 | 1 |
| IRS990/ConservationEasementsInd | 0 | 0 |
| IRS990/ConsolidatedAuditFinclStmtInd | 0 | 0 |
| IRS990/CreditCounselingInd | 0 | 0 |
| IRS990/CYBenefitsPaidToMembersAmt | 0 | 0 |
| IRS990/CYContributionsGrantsAmt | 0 | 654137 |
| IRS990/CYGrantsAndSimilarPaidAmt | 0 | 464311 |
| IRS990/CYInvestmentIncomeAmt | 0 | 96890 |
| IRS990/CYOtherExpensesAmt | 0 | 572816 |
| IRS990/CYOtherRevenueAmt | 0 | 0 |
| IRS990/CYProgramServiceRevenueAmt | 0 | 395168 |
| IRS990/CYRevenuesLessExpensesAmt | 0 | -312003 |
| IRS990/CYSalariesCompEmpBnftPaidAmt | 0 | 421071 |
| IRS990/CYTotalExpensesAmt | 0 | 1458198 |
| IRS990/CYTotalFundraisingExpenseAmt | 0 | 64763 |
| IRS990/CYTotalProfFndrsngExpnsAmt | 0 | 0 |
| IRS990/CYTotalRevenueAmt | 0 | 1146195 |
| IRS990/DecisionsSubjectToApprovaInd | 0 | 0 |
| IRS990/DeductibleArtContributionInd | 0 | 0 |
| IRS990/DeductibleNonCashContriInd | 0 | 0 |
| IRS990/DeferredRevenueGrp/BOYAmt | 0 | 19100 |
| IRS990/DeferredRevenueGrp/EOYAmt | 0 | 0 |
| IRS990/DelegationOfMgmtDutiesInd | 0 | 0 |
| IRS990/Desc | 0 | TRANSLATION TO THE CLINIC: ACCRF SUPPORTS AND COORDINATES RESEARCH INTO TREATMENTS MOST LIKELY TO LEAD TO CLINICAL EBENFIT FOR ADENOID CYSTIC CARCINOMA PATIENTS. DRUG DISCOVERY, DRUG DEVELOPMENT, PRECLINICAL DRUG SCREENING AND CORRELATIVE STUDIES ARE CRUCIAL TO THE INITIATION AND OPTIMAL CONDUCT OF CLINICAL TRIALS. |
| IRS990/DescribedInSection501c3Ind | 0 | 1 |
| IRS990/DisregardedEntityInd | 0 | 0 |
| IRS990/DocumentRetentionPolicyInd | 0 | 1 |
| IRS990/DonorAdvisedFundInd | 0 | 0 |
| IRS990/DonorRstrOrQuasiEndowmentsInd | 0 | 0 |
| IRS990/ElectionOfBoardMembersInd | 0 | 0 |
| IRS990/EmployeeCnt | 0 | 3 |
| IRS990/EmploymentTaxReturnsFiledInd | 0 | 1 |
| IRS990/EngagedInExcessBenefitTransInd | 0 | 0 |
| IRS990/ExpenseAmt | 0 | 787961 |
| IRS990/FamilyOrBusinessRlnInd | 0 | 1 |
| IRS990/FederalGrantAuditRequiredInd | 0 | 0 |
| IRS990/FeesForServicesAccountingGrp/ManagementAndGeneralAmt | 0 | 19204 |
| IRS990/FeesForServicesAccountingGrp/TotalAmt | 0 | 19204 |
| IRS990/FeesForServicesOtherGrp/FundraisingAmt | 0 | 1758 |
| IRS990/FeesForServicesOtherGrp/ManagementAndGeneralAmt | 0 | 2566 |
| IRS990/FeesForServicesOtherGrp/TotalAmt | 0 | 4324 |
| IRS990/ForeignActivitiesInd | 0 | 1 |
| IRS990/ForeignFinancialAccountInd | 0 | 0 |
| IRS990/ForeignGrantsGrp/ProgramServicesAmt | 0 | 96986 |
| IRS990/ForeignGrantsGrp/TotalAmt | 0 | 96986 |
| IRS990/ForeignOfficeInd | 0 | 0 |
| IRS990/Form8282PropertyDisposedOfInd | 0 | 0 |
| IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt | 0 | 50.00 |
| IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt | 1 | 5.00 |
| IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt | 2 | 5.00 |
| IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt | 3 | 35.00 |
| IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt | 4 | 5.00 |
| IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt | 5 | 5.00 |
| IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt | 6 | 5.00 |
| IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt | 7 | 5.00 |
| IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt | 8 | 40.00 |
| IRS990/Form990PartVIISectionAGrp/HighestCompensatedEmployeeInd | 0 | X |
| IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd | 0 | X |
| IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd | 1 | X |
| IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd | 2 | X |
| IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd | 3 | X |
| IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd | 4 | X |
| IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd | 5 | X |
| IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd | 6 | X |
| IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd | 7 | X |
| IRS990/Form990PartVIISectionAGrp/OfficerInd | 0 | X |
| IRS990/Form990PartVIISectionAGrp/OfficerInd | 1 | X |
| IRS990/Form990PartVIISectionAGrp/OfficerInd | 2 | X |
| IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt | 0 | 0 |
| IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt | 1 | 0 |
| IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt | 2 | 0 |
| IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt | 3 | 0 |
| IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt | 4 | 0 |
| IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt | 5 | 0 |
| IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt | 6 | 0 |
| IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt | 7 | 0 |
| IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt | 8 | 0 |
| IRS990/Form990PartVIISectionAGrp/PersonNm | 0 | JEFFREY A KAUFMAN |
| IRS990/Form990PartVIISectionAGrp/PersonNm | 1 | THOMAS DILENGE |
| IRS990/Form990PartVIISectionAGrp/PersonNm | 2 | RALPH MOLLIS |
| IRS990/Form990PartVIISectionAGrp/PersonNm | 3 | MARNIE A KAUFMAN |
| IRS990/Form990PartVIISectionAGrp/PersonNm | 4 | ELIZABETH WEHLAGE |
| IRS990/Form990PartVIISectionAGrp/PersonNm | 5 | DAVID MORSE |
| IRS990/Form990PartVIISectionAGrp/PersonNm | 6 | BOZHO TODORICH |
| IRS990/Form990PartVIISectionAGrp/PersonNm | 7 | EMMA KINLOCH |
| IRS990/Form990PartVIISectionAGrp/PersonNm | 8 | NICOLE SPARDY BURR |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt | 0 | 150000 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt | 1 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt | 2 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt | 3 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt | 4 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt | 5 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt | 6 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt | 7 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt | 8 | 142500 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt | 0 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt | 1 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt | 2 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt | 3 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt | 4 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt | 5 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt | 6 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt | 7 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt | 8 | 0 |
| IRS990/Form990PartVIISectionAGrp/TitleTxt | 0 | EXECUTIVE DIRECTOR/BOARD C |
| IRS990/Form990PartVIISectionAGrp/TitleTxt | 1 | BOARD VICE CHAIR |
| IRS990/Form990PartVIISectionAGrp/TitleTxt | 2 | TREASURER |
| IRS990/Form990PartVIISectionAGrp/TitleTxt | 3 | DIRECTOR & CFO |
| IRS990/Form990PartVIISectionAGrp/TitleTxt | 4 | DIRECTOR |
| IRS990/Form990PartVIISectionAGrp/TitleTxt | 5 | DIRECTOR |
| IRS990/Form990PartVIISectionAGrp/TitleTxt | 6 | DIRECTOR |
| IRS990/Form990PartVIISectionAGrp/TitleTxt | 7 | DIRECTOR |
| IRS990/Form990PartVIISectionAGrp/TitleTxt | 8 | DIRECTOR OF RESEARCH |
| IRS990/Form990ProvidedToGvrnBodyInd | 0 | 1 |
| IRS990/FormationYr | 0 | 2005 |
| IRS990/FormerOfcrEmployeesListedInd | 0 | 0 |
| IRS990/FSAuditedBasisGrp/SeparateBasisFinclStmtInd | 0 | X |
| IRS990/FSAuditedInd | 0 | 1 |
| IRS990/FundraisingActivitiesInd | 0 | 0 |
| IRS990/GamingActivitiesInd | 0 | 0 |
| IRS990/GoverningBodyVotingMembersCnt | 0 | 8 |
| IRS990/GrantAmt | 0 | 289350 |
| IRS990/GrantsPayableGrp/BOYAmt | 0 | 50000 |
| IRS990/GrantsPayableGrp/EOYAmt | 0 | 0 |
| IRS990/GrantsToDomesticOrgsGrp/ProgramServicesAmt | 0 | 367325 |
| IRS990/GrantsToDomesticOrgsGrp/TotalAmt | 0 | 367325 |
| IRS990/GrantsToIndividualsInd | 0 | 0 |
| IRS990/GrantsToOrganizationsInd | 0 | 1 |
| IRS990/GrantToRelatedPersonInd | 0 | 0 |
| IRS990/GrossReceiptsAmt | 0 | 1146195 |
| IRS990/GroupReturnForAffiliatesInd | 0 | 0 |
| IRS990/IncludeFIN48FootnoteInd | 0 | 1 |
| IRS990/IndependentAuditFinclStmtInd | 0 | 1 |
| IRS990/IndependentVotingMemberCnt | 0 | 6 |
| IRS990/IndivRcvdGreaterThan100KCnt | 0 | 2 |
| IRS990/IndoorTanningServicesInd | 0 | 0 |
| IRS990/InfoInScheduleOPartVIInd | 0 | X |
| IRS990/InsuranceGrp/ProgramServicesAmt | 0 | 521 |
| IRS990/InsuranceGrp/TotalAmt | 0 | 521 |
| IRS990/InvestmentIncomeGrp/ExclusionAmt | 0 | 96890 |
| IRS990/InvestmentIncomeGrp/TotalRevenueColumnAmt | 0 | 96890 |
| IRS990/InvestmentInJointVentureInd | 0 | 0 |
| IRS990/IRPDocumentCnt | 0 | 1 |
| IRS990/IRPDocumentW2GCnt | 0 | 0 |
| IRS990/LegalDomicileStateCd | 0 | MA |
| IRS990/LoanOutstandingInd | 0 | 0 |
| IRS990/LobbyingActivitiesInd | 0 | 0 |
| IRS990/LocalChaptersInd | 0 | 0 |
| IRS990/MaterialDiversionOrMisuseInd | 0 | 0 |
| IRS990/MembersOrStockholdersInd | 0 | 0 |
| IRS990/MethodOfAccountingAccrualInd | 0 | X |
| IRS990/MinutesOfCommitteesInd | 0 | 1 |
| IRS990/MinutesOfGoverningBodyInd | 0 | 1 |
| IRS990/MissionDesc | 0 | THE ADENOID CYSTIC CARCINOMA RESEARCH FOUNDATION (ACCRF) SUPPORTS RESEARCH INTO ADENOID CYSTIC CARCINOMA THAT WILL ACCELERATE THE DEVELOPMENT OF IMPROVED THERAPIES AND A CURE FOR THE DISEASE. |
| IRS990/MoreThan5000KToIndividualsInd | 0 | 0 |
| IRS990/MoreThan5000KToOrgInd | 0 | 1 |
| IRS990/NetAssetsOrFundBalancesBOYAmt | 0 | 2543644 |
| IRS990/NetAssetsOrFundBalancesEOYAmt | 0 | 2231641 |
| IRS990/NetUnrelatedBusTxblIncmAmt | 0 | 0 |
| IRS990/NoDonorRestrictionNetAssetsGrp/BOYAmt | 0 | 2543644 |
| IRS990/NoDonorRestrictionNetAssetsGrp/EOYAmt | 0 | 2231641 |
| IRS990/NondeductibleContributionsInd | 0 | 0 |
| IRS990/OfficeExpensesGrp/FundraisingAmt | 0 | 3349 |
| IRS990/OfficeExpensesGrp/ManagementAndGeneralAmt | 0 | 5154 |
| IRS990/OfficeExpensesGrp/ProgramServicesAmt | 0 | 36620 |
| IRS990/OfficeExpensesGrp/TotalAmt | 0 | 45123 |
| IRS990/OfficerMailingAddressInd | 0 | 0 |
| IRS990/OperateHospitalInd | 0 | 0 |
| IRS990/Organization501c3Ind | 0 | X |
| IRS990/OrganizationFollowsFASB117Ind | 0 | X |
| IRS990/OtherChangesInNetAssetsAmt | 0 | 0 |
| IRS990/OtherExpensesGrp/Desc | 0 | RESEARCH STUDIES EXPENS |
| IRS990/OtherExpensesGrp/Desc | 1 | DRUG SCREENING EXPENSE |
| IRS990/OtherExpensesGrp/Desc | 2 | STATE REGISTRATION AND |
| IRS990/OtherExpensesGrp/Desc | 3 | OTHER FEES |
| IRS990/OtherExpensesGrp/ProgramServicesAmt | 0 | 283148 |
| IRS990/OtherExpensesGrp/ProgramServicesAmt | 1 | 204639 |
| IRS990/OtherExpensesGrp/ProgramServicesAmt | 2 | 2165 |
| IRS990/OtherExpensesGrp/ProgramServicesAmt | 3 | 1499 |
| IRS990/OtherExpensesGrp/TotalAmt | 0 | 283148 |
| IRS990/OtherExpensesGrp/TotalAmt | 1 | 204639 |
| IRS990/OtherExpensesGrp/TotalAmt | 2 | 2165 |
| IRS990/OtherExpensesGrp/TotalAmt | 3 | 1499 |
| IRS990/OtherSalariesAndWagesGrp/FundraisingAmt | 0 | 34222 |
| IRS990/OtherSalariesAndWagesGrp/ManagementAndGeneralAmt | 0 | 58568 |
| IRS990/OtherSalariesAndWagesGrp/ProgramServicesAmt | 0 | 148764 |
| IRS990/OtherSalariesAndWagesGrp/TotalAmt | 0 | 241554 |
| IRS990/PartialLiquidationInd | 0 | 0 |
| IRS990/PayPremiumsPrsnlBnftCntrctInd | 0 | 0 |
| IRS990/PayrollTaxesGrp/FundraisingAmt | 0 | 4182 |
| IRS990/PayrollTaxesGrp/ManagementAndGeneralAmt | 0 | 7157 |
| IRS990/PayrollTaxesGrp/ProgramServicesAmt | 0 | 18178 |
| IRS990/PayrollTaxesGrp/TotalAmt | 0 | 29517 |
| IRS990/PoliticalCampaignActyInd | 0 | 0 |
| IRS990/PrepaidExpensesDefrdChargesGrp/BOYAmt | 0 | 21021 |
| IRS990/PrepaidExpensesDefrdChargesGrp/EOYAmt | 0 | 90 |
| IRS990/PrincipalOfficerNm | 0 | JEFFREY A KAUFMAN |
| IRS990/ProfessionalFundraisingInd | 0 | 0 |
| IRS990/ProgramServiceRevenueGrp/BusinessCd | 0 | 621500 |
| IRS990/ProgramServiceRevenueGrp/Desc | 0 | RESEARCH STUDIES |
| IRS990/ProgramServiceRevenueGrp/RelatedOrExemptFuncIncomeAmt | 0 | 395168 |
| IRS990/ProgramServiceRevenueGrp/TotalRevenueColumnAmt | 0 | 395168 |
| IRS990/ProgSrvcAccomActy2Grp/Desc | 0 | BASIC RESEARCH: ACCRF SUPPORTS AND COORDINATES THE DESCRIPTIVE AND FUNCTIONAL STUDIES THAT IDENTIFY MOLECULAR TARGETS AND PATHWAYS THAT PERMIT ADENOID CYSTIC CARCINOMA TO PROGRESS. BY FOCUSING ON THE MECHANISMS OF ACTION, RESEARCHERS MAY DISCOVER MORE QUICKLY THE ACHILLES' HEEL OF THE DISEASE. |
| IRS990/ProgSrvcAccomActy2Grp/ExpenseAmt | 0 | 476456 |
| IRS990/ProgSrvcAccomActy2Grp/GrantAmt | 0 | 174961 |
| IRS990/ProgSrvcAccomActy2Grp/RevenueAmt | 0 | 0 |
| IRS990/ProhibitedTaxShelterTransInd | 0 | 0 |
| IRS990/PYBenefitsPaidToMembersAmt | 0 | 0 |
| IRS990/PYContributionsGrantsAmt | 0 | 748287 |
| IRS990/PYExcessBenefitTransInd | 0 | 0 |
| IRS990/PYGrantsAndSimilarPaidAmt | 0 | 225883 |
| IRS990/PYInvestmentIncomeAmt | 0 | 90836 |
| IRS990/PYOtherExpensesAmt | 0 | 1255566 |
| IRS990/PYOtherRevenueAmt | 0 | 0 |
| IRS990/PYProgramServiceRevenueAmt | 0 | 1054422 |
| IRS990/PYRevenuesLessExpensesAmt | 0 | 20825 |
| IRS990/PYSalariesCompEmpBnftPaidAmt | 0 | 391271 |
| IRS990/PYTotalExpensesAmt | 0 | 1872720 |
| IRS990/PYTotalProfFndrsngExpnsAmt | 0 | 0 |
| IRS990/PYTotalRevenueAmt | 0 | 1893545 |
| IRS990/QuidProQuoContributionsInd | 0 | 0 |
| IRS990/RcvFndsToPayPrsnlBnftCntrctInd | 0 | 0 |
| IRS990/ReconcilationRevenueExpnssAmt | 0 | -312003 |
| IRS990/RegularMonitoringEnfrcInd | 0 | 1 |
| IRS990/RelatedEntityInd | 0 | 0 |
| IRS990/RelatedOrganizationCtrlEntInd | 0 | 0 |
| IRS990/ReportInvestmentsOtherSecInd | 0 | 0 |
| IRS990/ReportLandBuildingEquipmentInd | 0 | 0 |
| IRS990/ReportOtherAssetsInd | 0 | 0 |
| IRS990/ReportOtherLiabilitiesInd | 0 | 0 |
| IRS990/ReportProgramRelatedInvstInd | 0 | 0 |
| IRS990/RevenueAmt | 0 | 395168 |
| IRS990/SavingsAndTempCashInvstGrp/BOYAmt | 0 | 2067028 |
| IRS990/SavingsAndTempCashInvstGrp/EOYAmt | 0 | 2183175 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt | 0 | 654139 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus1YearAmt | 0 | 748287 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus2YearsAmt | 0 | 807996 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus3YearsAmt | 0 | 1588834 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus4YearsAmt | 0 | 787706 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt | 0 | 4586962 |
| IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearAmt | 0 | 96890 |
| IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus1YearAmt | 0 | 90836 |
| IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus2YearsAmt | 0 | 30851 |
| IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus3YearsAmt | 0 | 403 |
| IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus4YearsAmt | 0 | 10071 |
| IRS990ScheduleA/GrossInvestmentIncome170Grp/TotalAmt | 0 | 229051 |
| IRS990ScheduleA/GrossReceiptsRltdActivitiesAmt | 0 | 3249233 |
| IRS990ScheduleA/PublicOrganization170Ind | 0 | X |
| IRS990ScheduleA/PublicSupportCY170Pct | 0 | 0.70700 |
| IRS990ScheduleA/PublicSupportPY170Pct | 0 | 0.77020 |
| IRS990ScheduleA/PublicSupportTotal170Amt | 0 | 3405006 |
| IRS990ScheduleA/SubstantialContributorsTotAmt | 0 | 1181956 |
| IRS990ScheduleA/ThirtyThrPctSuprtTestsCY170Ind | 0 | X |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt | 0 | 654139 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt | 0 | 748287 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus2YearsAmt | 0 | 807996 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus3YearsAmt | 0 | 1588834 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus4YearsAmt | 0 | 787706 |
| IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt | 0 | 4586962 |
| IRS990ScheduleA/TotalSupportAmt | 0 | 4816013 |
| IRS990ScheduleB/ContributorInformationGrp/ContributorBusinessName/BusinessNameLine1 | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorNum | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine1 | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine2 | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/City | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/State | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/ZIPCode | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/TotalContributionsAmt | 0 | RESTRICTED |
| IRS990/ScheduleBRequiredInd | 0 | 1 |
| IRS990ScheduleD/DonatedServicesAndUseFcltsAmt | 0 | 37500 |
| IRS990ScheduleD/DonatedServicesUseFcltsAmt | 0 | 37500 |
| IRS990ScheduleD/ExpensesNotReportedAmt | 0 | 37500 |
| IRS990ScheduleD/ExpensesNotRptFinclStmtAmt | 0 | 0 |
| IRS990ScheduleD/ExpensesSubtotalAmt | 0 | 1458198 |
| IRS990ScheduleD/FootnoteTextInd | 0 | X |
| IRS990ScheduleD/RevenueNotReportedAmt | 0 | 37500 |
| IRS990ScheduleD/RevenueNotReportedFinclStmtAmt | 0 | 0 |
| IRS990ScheduleD/RevenueSubtotalAmt | 0 | 1146195 |
| IRS990ScheduleD/SupplementalInformationDetail/ExplanationTxt | 0 | THE FOUNDATION IS EXEMPT FROM INCOME TAXES AS A PUBLIC CHARITY UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. MANAGEMENT BELIEVES THAT THE FOUNDATION OPERATES IN A MANNER CONSISTENT WITH THEIR TAX-EXEMPT STATUS AT BOTH THE STATE AND FEDERAL LEVEL. THE FOUNDATION ANNUALLY FILES IRS FORM 990 - RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX, REPORTING VARIOUS INFORMATION THAT THE IRS USES TO MONITOR THE ACTIVITIES OF TAX-EXEMPT ENTITIES. THESE TAX RETURNS ARE SUBJECT TO REVIEW BY THE TAXING AUTHORITIES GENERALLY FOR A PERIOD OF THREE YEARS AFTER THEY WERE FILED. THE FOUNDATION CURRENTLY HAS NO TAX EXAMINATIONS IN PROGRESS. THE FOUNDATION EVALUATES ALL SIGNIFICANT TAX POSITIONS. AS OF DECEMBER 31, 2024, THE FOUNDATION DOES NOT BELIEVE THAT IT HAS TAKEN ANY TAX POSITIONS THAT WOULD REQUIRE THE RECORDING OF ANY ADDITIONAL TAX LIABILITY NOR DOES IT BELIEVE THAT THERE ARE ANY UNREALIZED TAX BENEFITS THAT WOULD EITHER INCREASE OR DECREASE WITHIN THE NEXT 12 MONTHS. THE FOUNDATION DID NOT PAY ANY INTEREST OR PENALTIES IN 2024. |
| IRS990ScheduleD/SupplementalInformationDetail/FormAndLineReferenceDesc | 0 | PART X, LINE 2: |
| IRS990ScheduleD/TotalBookValueLandBuildingsAmt | 0 | 0 |
| IRS990ScheduleD/TotalExpensesPerForm990Amt | 0 | 1458198 |
| IRS990ScheduleD/TotalRevenuePerForm990Amt | 0 | 1146195 |
| IRS990ScheduleD/TotalRevEtcAuditedFinclStmtAmt | 0 | 1183695 |
| IRS990ScheduleD/TotExpnsEtcAuditedFinclStmtAmt | 0 | 1495698 |
| IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt | 0 | 0 |
| IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt | 1 | 0 |
| IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt | 0 | 0 |
| IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt | 1 | 0 |
| IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt | 0 | 72013 |
| IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt | 1 | 24973 |
| IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt | 0 | EUROPE (INCLUDING ICELAND & GREENLAND) |
| IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt | 1 | EAST ASIA AND THE PACIFIC |
| IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt | 0 | MULTICENTER VALIDATION OF P63 IMMUNOHISTOCHEMISTRY (IHC) AS A PROGNOSTIC MARKER FOR ADENOID CYSTIC CARCINOMA (INSTITUTO PORTUGUS DE ONCOLOGIA DE LISBOA) (RADBOUND UNIVERSITY, NETHERLANDS & INSTITUTO PORTUGUES DE ONCOLOGIA DELISBOA, PORTUGAL) AND IDENTIFYING NOVEL TREATMENT OPTIONS AS WELL AS PREDICTIVE BIOMARKERS FOR EXISTING IMMUNE THERAPIES IN ADVANCED ACC (CHARITE COMPREHENSIVE CANCER CENTER, GERMANY) |
| IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt | 1 | A PRELUDE TOWARDS TRANSFORMING ADENOID CYSTIC CARCINOMA INTO AN IMMUNE HOT TUMOUR (MACQUARIE UNIVERSITY, AUSTRALIA) |
| IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt | 0 | GRANTS TO RECIPIENTS LOCATED IN REGION. |
| IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt | 1 | GRANTS TO RECIPIENTS LOCATED IN REGION. |
| IRS990ScheduleF/BoycottCountriesInd | 0 | 0 |
| IRS990ScheduleF/ContinuationSpentAmt | 0 | 0 |
| IRS990ScheduleF/ContinuationTotalEmployeeCnt | 0 | 0 |
| IRS990ScheduleF/ContinuationTotalOfficeCnt | 0 | 0 |
| IRS990ScheduleF/ForeignCorpOwnershipInd | 0 | 0 |
| IRS990ScheduleF/ForeignPartnershipInd | 0 | 0 |
| IRS990ScheduleF/GrantRecordsMaintainedInd | 0 | 0 |
| IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt | 0 | 43800 |
| IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt | 1 | 25000 |
| IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt | 2 | 24973 |
| IRS990ScheduleF/GrantsToOrgOutsideUSGrp/MannerOfCashDisbursementTxt | 0 | CHECK OR FUND TRANSFER |
| IRS990ScheduleF/GrantsToOrgOutsideUSGrp/MannerOfCashDisbursementTxt | 1 | CHECK OR FUND TRANSFER |
| IRS990ScheduleF/GrantsToOrgOutsideUSGrp/MannerOfCashDisbursementTxt | 2 | CHECK OR FUND TRANSFER |
| IRS990ScheduleF/GrantsToOrgOutsideUSGrp/NonCashAssistanceAmt | 0 | 0 |
| IRS990ScheduleF/GrantsToOrgOutsideUSGrp/NonCashAssistanceAmt | 1 | 0 |
| IRS990ScheduleF/GrantsToOrgOutsideUSGrp/NonCashAssistanceAmt | 2 | 0 |
| IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt | 0 | IDENTIFYING NOVEL TREATMENT OPTIONS AS WELL AS PREDICTIVE BIOMARKERS FOR EXISTING IMMUNE THERAPIES IN ADVANCED ACC. (CHARITE COMPREHENSIVE CANCER CENTER) |
| IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt | 1 | MULTICENTER VALIDATION OF P63 IMMUNOHISTOCHEMISTRY (IHC) AS A PROGNOSTIC MARKER FOR ADENOID CYSTIC CARCINOMA (RADBOUD) |
| IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt | 2 | A PRELUDE TOWARDS TRANSFORMING ADENOID CYSTIC CARCINOMA INTO AN IMMUNE HOT TUMOUR. (MACQUARIE UNIVERSITY) |
| IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt | 0 | GERMANY |
| IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt | 1 | NETHERLANDS |
| IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt | 2 | AUSTRALIA |
| IRS990ScheduleF/InterestInForeignTrustInd | 0 | 0 |
| IRS990ScheduleF/PassiveForeignInvestmestCoInd | 0 | 0 |
| IRS990ScheduleF/SubtotalEmployeesCnt | 0 | 0 |
| IRS990ScheduleF/SubtotalOfficesCnt | 0 | 0 |
| IRS990ScheduleF/SubtotalSpentAmt | 0 | 96986 |
| IRS990ScheduleF/SupplementalInformationDetail/ExplanationTxt | 0 | ALL FOREIGN GRANTS ARE MADE TO MAJOR RESEARCH INSTITUTIONS OR HOSPITALS WITH INTERNATIONAL REPUTATIONS. IN ADDITION TO INTERIM WRITTEN REPORTS ON RESEARCH PROJECTS AND A FINAL REPORT FOLLOWING PROJECT COMPLETION, ACCRF ANNUALLY MEETS WITH EACH OF THE FOREIGN GRANTEES TO RECEIVE AN ORAL REPORT ON THE RESEARCH PROJECTS. |
| IRS990ScheduleF/SupplementalInformationDetail/FormAndLineReferenceDesc | 0 | PART I, LINE 2: |
| IRS990ScheduleF/TotalEmployeeCnt | 0 | 0 |
| IRS990ScheduleF/TotalOfficeCnt | 0 | 0 |
| IRS990ScheduleF/TotalSpentAmt | 0 | 96986 |
| IRS990ScheduleF/TransferToForeignCorpInd | 0 | 0 |
| IRS990ScheduleI/GrantRecordsMaintainedInd | 0 | 1 |
| IRS990ScheduleI/RecipientTable/CashGrantAmt | 0 | 36768 |
| IRS990ScheduleI/RecipientTable/CashGrantAmt | 1 | 100000 |
| IRS990ScheduleI/RecipientTable/CashGrantAmt | 2 | 50000 |
| IRS990ScheduleI/RecipientTable/CashGrantAmt | 3 | 49989 |
| IRS990ScheduleI/RecipientTable/CashGrantAmt | 4 | 50000 |
| IRS990ScheduleI/RecipientTable/CashGrantAmt | 5 | 49999 |
| IRS990ScheduleI/RecipientTable/CashGrantAmt | 6 | 50000 |
| IRS990ScheduleI/RecipientTable/CashGrantAmt | 7 | 30569 |
| IRS990ScheduleI/RecipientTable/IRCSectionDesc | 0 | 501(C)(3) |
| IRS990ScheduleI/RecipientTable/IRCSectionDesc | 1 | 501(C)(3) |
| IRS990ScheduleI/RecipientTable/IRCSectionDesc | 2 | 501(C)(3) |
| IRS990ScheduleI/RecipientTable/IRCSectionDesc | 3 | 501(C)(3) |
| IRS990ScheduleI/RecipientTable/IRCSectionDesc | 4 | 501(C)(3) |
| IRS990ScheduleI/RecipientTable/IRCSectionDesc | 5 | 501(C)(3) |
| IRS990ScheduleI/RecipientTable/IRCSectionDesc | 6 | 501(C)(3) |
| IRS990ScheduleI/RecipientTable/IRCSectionDesc | 7 | 501(C)(3) |
| IRS990ScheduleI/RecipientTable/NonCashAssistanceAmt | 0 | 0 |
| IRS990ScheduleI/RecipientTable/NonCashAssistanceAmt | 1 | 0 |
| IRS990ScheduleI/RecipientTable/NonCashAssistanceAmt | 2 | 0 |
| IRS990ScheduleI/RecipientTable/NonCashAssistanceAmt | 3 | 0 |
| IRS990ScheduleI/RecipientTable/NonCashAssistanceAmt | 4 | 0 |
| IRS990ScheduleI/RecipientTable/NonCashAssistanceAmt | 5 | 0 |
| IRS990ScheduleI/RecipientTable/NonCashAssistanceAmt | 6 | 0 |
| IRS990ScheduleI/RecipientTable/NonCashAssistanceAmt | 7 | 0 |
| IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt | 0 | ADENOID CYSTIC CARCINOMA ARISING AT NON-SALIVARY SITES IN THE U.S.- A PROPOSAL FOR ANALYSIS OF TWO NATIONAL CANCER DATASETS. |
| IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt | 1 | CT-GUIDED LDR BRACHYTHERAPY FOR ADENOID CYSTIC CARCINOMA LUNG METASTASES: EFFICACY AND SAFETY OUTCOMES. |
| IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt | 2 | STEREOTACTIC BODY RADIOTHERAPY (SBRT) FOR EARLY TREATMENT OF OLIGOMETASTATIC ADENOID CYSTIC CARCINOMA: THE SOLAR TRIAL |
| IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt | 3 | TO STUDY THE EXPRESSION OF FLOWER-WIN AND FLOWER-LOSE IN ADENOID CYSTIC CARCINOMA (ACC) |
| IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt | 4 | VEGFR INHIBITORS IN ADENOID CYSTIC CARCINOMA |
| IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt | 5 | MOLECULAR CHARACTERIZATION OF THE SALIVARY ADENOID CYSTIC CARCINOMA TUMOR IMMUNE LANDSCAPE BY ANATOMIC SUBSITE |
| IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt | 6 | CHEMICAL PROTEOMICS TO TARGET MYB IN ACC |
| IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt | 7 | PATTERNS OF CARE IN THE MANAGEMENT OF PATIENTS WITH ADENOID CYSTIC CARCINOMA OF THE BREAST |
| IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt | 0 | BAYLOR COLLEGE OF MEDICINE |
| IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt | 1 | MISSION VIEJO HOSPITAL AND UCLA |
| IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt | 2 | DANA FARBER CANCER INSTITUTE |
No mirrored PDF or thumbnail assets are attached yet.